



PATENT
ATTORNEY DOCKET NO.: TNX 98-08-01
CUSTOMER NO: 26839

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:
THOMAS, David, et al.

Serial No.: 09/810,883

Filed: March 16, 2001

For: BISPECIFIC MOLECULES CROSS-
LINKING ITIM AND ITAM FOR
THERAPY

)
)
) Group Art Unit: 1614

)
) Examiner: To Be Assigned
)
)
)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

**RESPONSE TO NOTICE TO FILE MISSING PARTS and
PRELIMINARY AMENDMENT**

Applicants hereby submit the executed declaration for this application along with
the required declaration surcharge of \$65.00.

An additional claims fee of \$107.00 (2 independent claims (\$80.00) and 3
dependent claims (\$27.00)) is also attached. If any additional fees are due, please
charge the deposit account # 20-0087.

Before examination of this application, please enter the following amendments:

IN THE SPECIFICATION:

Please insert the following sentence as the first line of the specification:

--This application is a continuation-in-part of U.S. Application No. 09/440,310,
filed November 17, 1999, and claims priority under 35 U.S.C. §119e to U.S. Provisional
Application No. 60/108,816 filed on November 17, 1998.--

09810883-06501

IN THE CLAIMS:

Please add the following new claims:

24. A bispecific antibody that targets an ITAM and an ITIM receptor on mast cells or basophils which inhibits the release of TNF- α from mast cells or basophils.
25. The bispecific antibody of claim 24, wherein the ITAM is Fc ϵ RI and the ITIM is Fc ϵ RII.
26. The bispecific antibody of claim 24, wherein the inhibition of histamine release is most effective at an antibody concentration ranging from 0.1 to 1 μ g/ml.
27. A method of inhibiting the release of TNF- α from mast cells comprising administering to a patient in need of such treatment an effective amount of a bispecific antibody that targets an ITAM and an ITIM receptor on mast cells or basophils.
28. The method of claim 27, wherein the bispecific antibody targets the ITAM Fc ϵ RI and the ITIM Fc ϵ RII.--


09810883-061501

REMARKS

Claims 1-28 are now pending in this application. Applicants have added new claims 24-28. Support for these claims can be found in the specification as a whole, for example in figure 10, pages 4-5, and page 23. No new matter has been introduced by these amendments.

Respectfully Submitted,

Dated: June 15, 2001.

BY: 
Cheryl A. Liljestrand
Reg. No. 45,275

09/810,883-0150
TNX 98-08-01